AR050902A1 - Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion - Google Patents
Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicionInfo
- Publication number
- AR050902A1 AR050902A1 ARP050101627A ARP050101627A AR050902A1 AR 050902 A1 AR050902 A1 AR 050902A1 AR P050101627 A ARP050101627 A AR P050101627A AR P050101627 A ARP050101627 A AR P050101627A AR 050902 A1 AR050902 A1 AR 050902A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- cr7r7
- hydrogen
- aryl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000002131 composite material Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- 150000002431 hydrogen Chemical class 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 2
- 125000005343 heterocyclic alkyl group Chemical group 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 206010014561 Emphysema Diseases 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 229910002651 NO3 Inorganic materials 0.000 abstract 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 abstract 1
- 206010061876 Obstruction Diseases 0.000 abstract 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 abstract 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004373 acetylcholine Drugs 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- -1 quinuclidine compound Chemical class 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Abstract
Un compuesto de quinuclidina que tiene la formula (1) tal como se indica, en el que: R1 se selecciona entre el grupo que consiste en nada, hidrogeno, alquilo C1-15, alquilo C1-15 sustituido con halogeno, alquilC1-15-cicloalquilo, cicloalquilo, alquenilo C2-15, alquilo C1-15 sustituido con hidrogeno, alquilC1-15-arilo, alquilC1-15-heteroarilo, (CR7R7)qNRaRa, (CR7R7)qNC(O)Ra, (CR7R7)qC(O)NRaRa, (CR7R7)qC(O)Ra, (CR7R7)qOC(O)Ra, (CR7R7)qNRaC(O)NRaRa, (CR7R7)qOCRc y (CR7R7)qNS(O)Ra, o R1 se selecciona entre el grupo que consiste en las formulas (2) y (3) o R1 se selecciona entre el grupo que consiste en la formula (4), R2 y R3 se seleccionan independientemente entre el grupo que consiste en arilo, alquilC1-4arilo, heteroarilo, alquilC1- 4-heteroarilo, resto heterocíclico y alquiloC1-4heterocíclico, donde todos estos restos pueden estar opcionalmente sustituidos; Ra se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-15, alcoxi C1-15, arilo, alquilC1-1-5-arilo, heteroarilo, alquilC1-15-heteroarilo, resto heterocíclico y alquiloC1-15heterocíclico, en donde todos pueden estar opcionalmente sustituidos; Rc se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-15, alcoxi C1-15, resto heterocíclico y alquiloC1-15heterocíclico, en donde todos pueden estar opcionalmente sustituidos; R4 y R5 se seleccionan independientemente entre el grupo que consiste en hidrogeno, halogeno, alquilo C1-4, arilo, alquilC1-4-arilo, ciano, nitro, (CR7R7)qORb, (CR7R7)qNRbRb o R4 y R5 juntos pueden formar un anillo de 5 a 6 miembros saturado o insaturado; y en los que los grupos heterocíclicos, heterocicloalquilo, alquilo, arilo, arilalquilo, heteroarilo y heteroalquilo pueden estar opcionalmente sustituidos; R6 se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-4; q es 0 o un entero que tiene un valor de 1 a 15; n es un entero que tiene un valor de 1 a 14; m es un entero que tiene un valor de 1 a 15; 1 es un entero que tiene un valor de 1 a 4; t es 0 o un entero que tiene un valor de 1 a 5; p es 0 o un entero que tiene un valor de 1 a 4; X, Y, Z y W se seleccionan independientemente entre el grupo que consiste en hidrogeno, alquilo C1-4; V se selecciona entre el grupo que consiste en CH2, O, S y NRb; M es O o CH2; Rb se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-4, arilo y alquilC1-4arilo; R7 se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-4, alquilo C1-4 sustituido con halogeno y alquilo C1-4 sustituido con hidrogeno; X- es un anion fisiologicamente aceptable, como cloruro, bromuro, yoduro, hidroxido, sulfato, nitrato, fosfato, acetato, trifluoroacetato, fumarato, citrato, tartrato, oxalato, succinato, mandelato, metansulfonato y p-toluensulfonato. Una composicion farmacéutica para el tratamiento de enfermedades mediadas por el receptor de acetilcolina muscarínico, que comprende el compuesto de la formula (1), y un vehículo farmacéuticamente aceptable para él. Uso del compuesto de la formula (1) para preparar una composicion farmacéutica de utilidad para tratar una enfermedad mediada por el receptor de acetilcolina muscarínico, en la que la acetilcolina se une a dicho receptor, mediante la administracion de una cantidad segura y eficaz de dicho compuesto. La enfermedad se selecciona del grupo que consiste en la enfermedad pulmonar obstructiva cronica, bronquitis cronica, asma, obstruccion respiratoria cronica, fibrosis pulmonar, enfisema pulmonar y rinitis alérgica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56562304P | 2004-04-27 | 2004-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050902A1 true AR050902A1 (es) | 2006-12-06 |
Family
ID=35242158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101627A AR050902A1 (es) | 2004-04-27 | 2005-04-25 | Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion |
Country Status (38)
| Country | Link |
|---|---|
| US (9) | US7498440B2 (es) |
| EP (3) | EP1740177B1 (es) |
| JP (2) | JP5014121B2 (es) |
| KR (2) | KR101152032B1 (es) |
| CN (2) | CN102040602A (es) |
| AP (1) | AP2213A (es) |
| AR (1) | AR050902A1 (es) |
| AU (1) | AU2005237576B2 (es) |
| BE (1) | BE2014C063I2 (es) |
| BR (1) | BRPI0510170B8 (es) |
| CA (2) | CA2755954C (es) |
| CY (3) | CY1113196T1 (es) |
| DK (2) | DK2570128T3 (es) |
| EA (2) | EA015033B1 (es) |
| EC (1) | ECSP066940A (es) |
| ES (2) | ES2600405T3 (es) |
| FR (1) | FR14C0075I2 (es) |
| HR (2) | HRP20120832T1 (es) |
| HU (2) | HUE031304T2 (es) |
| IL (1) | IL178152A (es) |
| LT (1) | LT2570128T (es) |
| LU (1) | LU92565I2 (es) |
| MA (1) | MA28631B1 (es) |
| MX (1) | MXPA06012405A (es) |
| MY (1) | MY144753A (es) |
| NL (1) | NL300694I1 (es) |
| NO (3) | NO338959B1 (es) |
| NZ (1) | NZ549997A (es) |
| PE (1) | PE20060259A1 (es) |
| PL (2) | PL2570128T3 (es) |
| PT (2) | PT2570128T (es) |
| SG (1) | SG186597A1 (es) |
| SI (2) | SI1740177T1 (es) |
| TW (1) | TWI363759B (es) |
| UA (1) | UA95768C2 (es) |
| UY (1) | UY28871A1 (es) |
| WO (1) | WO2005104745A2 (es) |
| ZA (1) | ZA200608565B (es) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045914A1 (es) * | 2003-07-17 | 2005-11-16 | Glaxo Group Ltd | Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima |
| EA200600787A1 (ru) * | 2003-10-17 | 2006-08-25 | Глэксо Груп Лимитед | Антагонисты мускариновых ацетилхолиновых рецепторов |
| TW200524577A (en) * | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| JP2007528420A (ja) * | 2004-03-11 | 2007-10-11 | グラクソ グループ リミテッド | 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト |
| WO2005095407A1 (en) * | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| EP1725238A4 (en) * | 2004-03-17 | 2009-04-01 | Glaxo Group Ltd | M 3 MUSCARINACETYLCHOLINE RECEPTOR ANTAGONISTS |
| WO2006085890A2 (en) * | 2004-04-05 | 2006-08-17 | Samaritan Pharmaceuticals, Inc. | Anti-hiv quinuclidine compounds |
| MY144753A (en) | 2004-04-27 | 2011-10-31 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| JP2007537261A (ja) * | 2004-05-13 | 2007-12-20 | グラクソ グループ リミテッド | ムスカリン性アセチルコリン受容体アンタゴニスト |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| US7932247B2 (en) * | 2004-11-15 | 2011-04-26 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| JP2009503099A (ja) * | 2005-08-02 | 2009-01-29 | グラクソ グループ リミテッド | Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト |
| WO2007022351A2 (en) * | 2005-08-18 | 2007-02-22 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
| TW200811111A (en) | 2006-04-20 | 2008-03-01 | Glaxo Group Ltd | Novel compounds |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| WO2008015416A1 (en) | 2006-08-01 | 2008-02-07 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| TW201000476A (en) | 2008-02-06 | 2010-01-01 | Glaxo Group Ltd | Dual pharmacophores-PDE4-muscarinic antagonistics |
| AR070563A1 (es) | 2008-02-06 | 2010-04-21 | Glaxo Group Ltd | Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias. |
| TW200946526A (en) | 2008-02-06 | 2009-11-16 | Glaxo Group Ltd | Dual pharmacophores-PDE4-muscarinic antagonistics |
| ES2566339T3 (es) | 2008-06-05 | 2016-04-12 | Glaxo Group Limited | Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas |
| JP5502077B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規な化合物 |
| WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| EP3578169B1 (en) | 2009-02-26 | 2024-06-26 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| EP2406249A1 (en) | 2009-03-10 | 2012-01-18 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| EP2408769A1 (en) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
| ES2644724T3 (es) | 2009-04-30 | 2017-11-30 | Glaxo Group Limited | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas |
| WO2011029896A1 (en) | 2009-09-11 | 2011-03-17 | Glaxo Group Limited | Methods of preparation of muscarinic acetylcholine receptor antagonists |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| EP2507226A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Novel compounds |
| US20120238571A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Indazole derivatives as pi 3-kinase |
| JP2013512879A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体 |
| KR101781237B1 (ko) * | 2010-01-28 | 2017-09-22 | 테론 파마슈티칼즈, 인크. | 7-아조니아바이시클로〔2.2.1〕헵탄 유도체, 제조 방법, 및 그의 제약적 용도 |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| NZ604983A (en) * | 2010-06-22 | 2014-07-25 | Chiesi Farma Spa | Dry powder formulation comprising an antimuscarinic drug |
| HUE026059T2 (en) | 2010-09-08 | 2016-05-30 | Glaxosmithkline Ip Dev Ltd | N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] Polymorphs and salts of 2 - (methyloxy) -3-pyridinyl] methanesulfonamide |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| AU2012266540A1 (en) | 2011-06-08 | 2014-01-09 | Glaxo Group Limited | Dry powder inhaler compositions comprising umeclidinium |
| PE20141048A1 (es) * | 2011-06-08 | 2014-09-08 | Glaxo Group Ltd | Combinacion que comprende umeclidinio y un corticosteroide |
| CA2869849A1 (en) | 2012-04-13 | 2013-10-17 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate |
| RU2502743C1 (ru) * | 2012-08-03 | 2013-12-27 | Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) | Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору |
| EP3401316B1 (en) * | 2012-08-15 | 2021-08-04 | Glaxo Group Limited | Chemical process |
| GB201222679D0 (en) | 2012-12-17 | 2013-01-30 | Glaxo Group Ltd | Pharmaceutical combination products |
| KR101823451B1 (ko) | 2013-07-13 | 2018-01-30 | 베이징 에프에스웰컴 테크놀로지 디벨롭먼트 컴퍼니 리미티드 | 퀴논계 화합물, 이의 광학 이성질체 및 이의 제조 방법과 의약 용도 |
| CN105555269A (zh) | 2013-07-30 | 2016-05-04 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于治疗过度出汗的局部组合物及其使用方法 |
| US20160263109A1 (en) | 2013-10-17 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | P13k inhibitor for treatment of respiratory disease |
| AU2014336250A1 (en) | 2013-10-17 | 2016-04-14 | Glaxosmithkline Intellectual Property Development Limited | PI3K inhibitor for treatment of respiratory disease |
| JP2017515840A (ja) | 2014-05-12 | 2017-06-15 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | 感染症を治療するためのダニリキシンを含む医薬組成物 |
| ES2959699T3 (es) | 2014-05-28 | 2024-02-27 | Glaxosmithkline Ip Dev Ltd | Furoato de fluticasona en el tratamiento de la EPOC |
| US10023535B2 (en) | 2014-11-03 | 2018-07-17 | Olon S.P.A. | Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters |
| KR101613245B1 (ko) | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| CN105461710A (zh) * | 2015-10-23 | 2016-04-06 | 安徽德信佳生物医药有限公司 | 一种芜地溴铵的制备方法 |
| MX384539B (es) * | 2016-01-08 | 2025-03-14 | Theron Pharmaceuticals Inc | Composiciones de inhalador de polvo seco de derivados de 7-azoniabiciclo[2.2.1]heptano |
| GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| CN107200734B (zh) * | 2016-03-18 | 2019-12-24 | 益方生物科技（上海）有限公司 | 奎宁环衍生物及其制备方法和用途 |
| EP3248970A1 (en) | 2016-05-27 | 2017-11-29 | Zentiva K.S. | Forms of umeclidinium bromide |
| EP3497100A1 (en) | 2016-08-08 | 2019-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
| PT109740B (pt) * | 2016-11-14 | 2020-07-30 | Hovione Farmaciencia Sa | Processo para a preparação de brometo de umeclidínio |
| WO2018163212A1 (en) * | 2017-03-08 | 2018-09-13 | Gbr Laboratories Pvt. Ltd | A process for the preparation of umeclidinium bromide and intermediates thereof |
| GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| IT201700058796A1 (it) | 2017-05-30 | 2018-11-30 | Olon Spa | Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio. |
| GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| CN108558860B (zh) * | 2018-06-04 | 2020-12-25 | 成都伊诺达博医药科技有限公司 | 一种合成芜地溴铵的方法 |
| US11484531B2 (en) | 2018-08-30 | 2022-11-01 | Theravance Biopharma R&D Ip, Llc | Methods for treating chronic obstructive pulmonary disease |
| PT115583B (pt) | 2019-06-17 | 2022-05-02 | Hovione Farm S A | Processo contínuo para a preparação de medicamentos anticolinérgicos |
| CN113387923A (zh) * | 2020-03-13 | 2021-09-14 | 诺华股份有限公司 | 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法 |
| CA3173172A1 (en) | 2020-03-26 | 2021-09-30 | Christopher D. Kane | Cathepsin inhibitors for preventing or treating viral infections |
| CN111484445B (zh) * | 2020-04-21 | 2021-05-18 | 广东莱佛士制药技术有限公司 | 分离纯化高纯度乌美溴铵的中间体的方法 |
| CN115397823B (zh) * | 2020-04-26 | 2025-11-11 | 北京硕佰医药科技有限责任公司 | 一种m受体拮抗剂的晶体、制备方法及其应用 |
| CA3192236A1 (en) | 2020-09-10 | 2022-03-17 | Tony Lahoutte | Antibody fragment against fap |
| CN112479983B (zh) * | 2020-11-25 | 2022-07-12 | 江苏豪森药业集团有限公司 | 乌美溴铵中间体及其制备方法 |
| PT117440B (pt) | 2021-09-03 | 2024-04-26 | Hovione Farm S A | Processo para a preparação de aminas cíclicas cloroaquilo substituídas |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| WO2024251812A1 (en) | 2023-06-07 | 2024-12-12 | Pharmazell Gmbh | A process for the preparation of umeclidinium bromide intermediate |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2800481A (en) * | 1955-07-01 | 1957-07-23 | Smith Kline French Lab | Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof |
| US2800478A (en) * | 1955-07-01 | 1957-07-23 | Smith Kline French Lab | 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof |
| AT298118B (de) * | 1967-06-08 | 1972-04-25 | Siemens Ag | Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens |
| GB1242211A (en) | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
| GB1230087A (es) | 1967-08-17 | 1971-04-28 | ||
| GB1381872A (en) | 1971-06-22 | 1975-01-29 | Fisons Ltd | Pharmaceutical compositions for inhalation |
| GB2064336B (en) | 1979-12-06 | 1984-03-14 | Glaxo Group Ltd | Device for dispensing medicaments |
| DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
| IT1203660B (it) | 1982-10-08 | 1989-02-15 | Glaxo Group Ltd | Dispositivi per somministrare farmaci a pazienti e confezione di blister per essi |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| GB2178965B (en) | 1985-07-30 | 1988-08-03 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| IT1204826B (it) | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| US5780466A (en) * | 1995-01-30 | 1998-07-14 | Sanofi | Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present |
| US6350758B1 (en) * | 1996-12-02 | 2002-02-26 | Georgetown University | Tropane derivatives and method for their synthesis |
| US6248752B1 (en) * | 1998-02-27 | 2001-06-19 | Charles Duane Smith | Azabicyclooctane compositions and methods for enhancing chemotherapy |
| US6262066B1 (en) * | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CA2433128C (en) * | 2000-12-28 | 2010-05-25 | Almirall Prodesfarma Ag | Novel quinuclidine derivatives and medicinal compositions containing the same |
| HUP0401849A3 (en) * | 2001-10-17 | 2007-05-02 | Ucb Sa | Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
| EP1442037A1 (en) * | 2001-11-09 | 2004-08-04 | PHARMACIA & UPJOHN COMPANY | Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands |
| EA006505B1 (ru) * | 2001-12-20 | 2005-12-29 | Лабораториос С.А.Л.В.А.Т.,С.А. | Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора |
| US6696462B2 (en) * | 2002-01-31 | 2004-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| ES2204295B1 (es) * | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| AR040779A1 (es) | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion |
| WO2004091482A2 (en) | 2003-04-07 | 2004-10-28 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| AR048573A1 (es) | 2003-07-17 | 2006-05-10 | Glaxo Group Ltd | Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima |
| AR045914A1 (es) * | 2003-07-17 | 2005-11-16 | Glaxo Group Ltd | Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima |
| TW200523261A (en) | 2003-07-17 | 2005-07-16 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| SG147436A1 (en) | 2003-10-14 | 2008-11-28 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| EA200600787A1 (ru) | 2003-10-17 | 2006-08-25 | Глэксо Груп Лимитед | Антагонисты мускариновых ацетилхолиновых рецепторов |
| TW200524577A (en) | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| CN100569760C (zh) * | 2003-11-21 | 2009-12-16 | 施万制药 | 具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物 |
| AR046783A1 (es) | 2003-12-03 | 2005-12-21 | Glaxo Group Ltd | Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima |
| AR046784A1 (es) | 2003-12-03 | 2005-12-21 | Glaxo Group Ltd | Compuesto de amina ciclica composicion farmaceutica que lo comprende y su uso para preparar esta ultima |
| TW200534855A (en) | 2004-01-13 | 2005-11-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| WO2005086873A2 (en) | 2004-03-11 | 2005-09-22 | Glaxo Group Limited | Novel m3 muscarinic acetylcholine receptor antagonists |
| JP2007528420A (ja) | 2004-03-11 | 2007-10-11 | グラクソ グループ リミテッド | 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト |
| WO2005094835A1 (en) | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| WO2005094834A1 (en) | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
| EP1725238A4 (en) | 2004-03-17 | 2009-04-01 | Glaxo Group Ltd | M 3 MUSCARINACETYLCHOLINE RECEPTOR ANTAGONISTS |
| WO2005095407A1 (en) | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| EP1732923A2 (en) | 2004-04-07 | 2006-12-20 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
| MY144753A (en) | 2004-04-27 | 2011-10-31 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| JP2007537261A (ja) | 2004-05-13 | 2007-12-20 | グラクソ グループ リミテッド | ムスカリン性アセチルコリン受容体アンタゴニスト |
| TW200606161A (en) | 2004-05-28 | 2006-02-16 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| JP2008505118A (ja) | 2004-06-30 | 2008-02-21 | グラクソ グループ リミテッド | ムスカリン性アセチルコリン受容体アンタゴニスト |
| EP1781104A4 (en) | 2004-08-05 | 2008-05-21 | Glaxo Group Ltd | ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR |
| EP1781103A4 (en) | 2004-08-06 | 2008-05-14 | Glaxo Group Ltd | ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR |
| EP1824483A4 (en) | 2004-10-29 | 2009-11-04 | Glaxo Group Ltd | ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS |
| JP2008520573A (ja) | 2004-11-15 | 2008-06-19 | グラクソ グループ リミテッド | 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト |
| US7932247B2 (en) | 2004-11-15 | 2011-04-26 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| PE20061162A1 (es) | 2004-12-06 | 2006-10-14 | Smithkline Beecham Corp | Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos |
| PE20060826A1 (es) | 2004-12-06 | 2006-10-08 | Smithkline Beecham Corp | Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende |
| WO2006065788A2 (en) | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Novel muscarinic acetylcholine receptor antagonists |
| WO2006065755A2 (en) | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists |
| WO2007018514A1 (en) | 2005-07-28 | 2007-02-15 | Glaxo Group Limited | Novel m3 muscarinic acetylcholine receptor antagonists |
| WO2007018508A1 (en) | 2005-07-28 | 2007-02-15 | Glaxo Group Limited | Novel m3 muscarinic acetycholine receptor antagonists |
| JP2009503099A (ja) | 2005-08-02 | 2009-01-29 | グラクソ グループ リミテッド | Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト |
| WO2007016650A2 (en) | 2005-08-02 | 2007-02-08 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| WO2007022351A2 (en) | 2005-08-18 | 2007-02-22 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
| GB0921075D0 (en) * | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
-
2005
- 2005-04-25 MY MYPI20051806A patent/MY144753A/en unknown
- 2005-04-25 TW TW094113034A patent/TWI363759B/zh active
- 2005-04-25 AR ARP050101627A patent/AR050902A1/es active IP Right Grant
- 2005-04-25 UY UY28871A patent/UY28871A1/es not_active Application Discontinuation
- 2005-04-25 PE PE2005000457A patent/PE20060259A1/es active IP Right Grant
- 2005-04-27 LT LTEP12170402.7T patent/LT2570128T/lt unknown
- 2005-04-27 PT PT121704027T patent/PT2570128T/pt unknown
- 2005-04-27 PL PL12170402T patent/PL2570128T3/pl unknown
- 2005-04-27 US US11/568,330 patent/US7498440B2/en not_active Expired - Lifetime
- 2005-04-27 HR HRP20120832TT patent/HRP20120832T1/hr unknown
- 2005-04-27 UA UAA200611253A patent/UA95768C2/ru unknown
- 2005-04-27 MX MXPA06012405A patent/MXPA06012405A/es active IP Right Grant
- 2005-04-27 DK DK12170402.7T patent/DK2570128T3/en active
- 2005-04-27 EA EA200601991A patent/EA015033B1/ru not_active IP Right Cessation
- 2005-04-27 EP EP05746609A patent/EP1740177B1/en not_active Expired - Lifetime
- 2005-04-27 SG SG2012087052A patent/SG186597A1/en unknown
- 2005-04-27 ES ES12170402.7T patent/ES2600405T3/es not_active Expired - Lifetime
- 2005-04-27 SI SI200531605T patent/SI1740177T1/sl unknown
- 2005-04-27 CA CA2755954A patent/CA2755954C/en not_active Expired - Lifetime
- 2005-04-27 EP EP16177012.8A patent/EP3111936A1/en not_active Withdrawn
- 2005-04-27 EA EA201100019A patent/EA021994B1/ru not_active IP Right Cessation
- 2005-04-27 PL PL05746609T patent/PL1740177T3/pl unknown
- 2005-04-27 AP AP2006003746A patent/AP2213A/xx active
- 2005-04-27 KR KR1020117001909A patent/KR101152032B1/ko not_active Expired - Lifetime
- 2005-04-27 DK DK05746609.6T patent/DK1740177T3/da active
- 2005-04-27 AU AU2005237576A patent/AU2005237576B2/en active Active
- 2005-04-27 CA CA2564742A patent/CA2564742C/en not_active Expired - Lifetime
- 2005-04-27 SI SI200532099A patent/SI2570128T1/sl unknown
- 2005-04-27 NZ NZ549997A patent/NZ549997A/en not_active IP Right Cessation
- 2005-04-27 HU HUE12170402A patent/HUE031304T2/hu unknown
- 2005-04-27 CN CN2010105580787A patent/CN102040602A/zh active Pending
- 2005-04-27 PT PT05746609T patent/PT1740177E/pt unknown
- 2005-04-27 KR KR1020067022276A patent/KR101037026B1/ko not_active Expired - Lifetime
- 2005-04-27 JP JP2007510915A patent/JP5014121B2/ja not_active Expired - Lifetime
- 2005-04-27 EP EP12170402.7A patent/EP2570128B1/en not_active Expired - Lifetime
- 2005-04-27 BR BRPI0510170A patent/BRPI0510170B8/pt active IP Right Grant
- 2005-04-27 WO PCT/US2005/014386 patent/WO2005104745A2/en not_active Ceased
- 2005-04-27 ES ES05746609.6T patent/ES2392848T4/es not_active Expired - Lifetime
- 2005-04-27 CN CNA2005800215360A patent/CN1976701A/zh active Pending
-
2006
- 2006-09-18 IL IL178152A patent/IL178152A/en active Protection Beyond IP Right Term
- 2006-10-13 ZA ZA2006/08565A patent/ZA200608565B/en unknown
- 2006-10-20 EC EC2006006940A patent/ECSP066940A/es unknown
- 2006-10-31 MA MA29426A patent/MA28631B1/fr unknown
- 2006-11-24 NO NO20065417A patent/NO338959B1/no active Protection Beyond IP Right Term
-
2007
- 2007-07-09 US US11/774,867 patent/US7488827B2/en active Active
-
2009
- 2009-01-14 US US12/353,436 patent/US8183257B2/en not_active Expired - Lifetime
-
2012
- 2012-02-22 US US13/401,890 patent/US8309572B2/en not_active Expired - Lifetime
- 2012-04-13 JP JP2012092339A patent/JP5398871B2/ja not_active Expired - Lifetime
- 2012-09-26 US US13/627,007 patent/US8575347B2/en not_active Expired - Fee Related
- 2012-10-17 CY CY20121100965T patent/CY1113196T1/el unknown
-
2013
- 2013-10-14 US US14/052,816 patent/US8853404B2/en not_active Expired - Lifetime
-
2014
- 2014-09-04 US US14/476,940 patent/US9045469B2/en not_active Expired - Lifetime
- 2014-09-26 HU HUS1400053C patent/HUS1400053I1/hu unknown
- 2014-10-02 LU LU92565C patent/LU92565I2/xx unknown
- 2014-10-02 NL NL300694C patent/NL300694I1/nl unknown
- 2014-10-02 BE BE2014C063C patent/BE2014C063I2/fr unknown
- 2014-10-02 FR FR14C0075C patent/FR14C0075I2/fr active Active
- 2014-10-03 CY CY2014043C patent/CY2014043I1/el unknown
-
2015
- 2015-05-08 US US14/707,543 patent/US9144571B2/en not_active Expired - Lifetime
- 2015-09-10 US US14/849,775 patent/US20160002220A1/en not_active Abandoned
-
2016
- 2016-10-10 CY CY20161101008T patent/CY1118082T1/el unknown
- 2016-10-25 HR HRP20161385TT patent/HRP20161385T1/hr unknown
-
2017
- 2017-05-04 NO NO2017018C patent/NO2017018I2/no unknown
- 2017-05-04 NO NO2017017C patent/NO2017017I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050902A1 (es) | Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion | |
| AR048266A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende y su uso para prepararla | |
| AR035410A1 (es) | Derivados de carbamatos de quinuclidina que poseen elevada afinidad con los receptores muscarinicos y sus sales, inclusive sus sales quaternarias de amonio; composiciones farmaceuticas que comprenden dichos derivados o sus sales; proceso para preparar los derivados de carbamatos y productos de combi | |
| AR035497A1 (es) | Compuestos no-imidazol, composicion farmaceutica que los comprenden y el uso de los mismos para la preparacion de medicamentos | |
| AR062684A1 (es) | Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos | |
| AR046103A1 (es) | Compuesto de 8-azoniabiciclo [3.2.1] octano,composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion | |
| AR049263A1 (es) | Heterociclos biciclicos inhibidores de quinasa utiles como agentes anticancer | |
| AR062683A1 (es) | Compuestos derivados de piridin-4-ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos | |
| AR019478A1 (es) | Ligandos derivados de piperidina de alta afinidad para el receptor de nociceptina orl-1, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos. | |
| AR036040A1 (es) | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen | |
| PE20081164A1 (es) | Nuevos compuestos 521 | |
| AR064524A1 (es) | Derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, su preparacion, intermediarios para su sintesis, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por los receptores de tipo trpv1. | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| ECSP034431A (es) | N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina | |
| AR037740A1 (es) | Compuestos azabiciclicos sustituidos de heteroarilos fusionados para el tratamiento de enfermedades, composiciones farmaceuticas, su uso en la preparacion de medicamentos | |
| AR035431A1 (es) | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos | |
| AR037851A1 (es) | Antagonistas de neuroquinina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentos | |
| ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
| PE20020721A1 (es) | Derivados de quinuclidina como agentes antimuscarinicos m3 | |
| AR076859A1 (es) | Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
| AR035532A1 (es) | Diaminotiazoles, composiciones farmaceuticas que los comprenden, intermediarios para la preparacion de dichos compuestos, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos | |
| JP2005516067A5 (es) | ||
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
| AR034547A1 (es) | Derivados de indolin-2-ona, su utilizacion, procedimiento para su preparacion, composicion farmaceutica que lo contiene, medicamento que consiste en dicho derivado, y un producto que contiene dicho derivado y un antagonista de los receptores de la vasopresina | |
| PE20240886A1 (es) | Compuestos espirociclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |